HC Wainwright Has Strong Estimate for ASND FY2026 Earnings

Ascendis Pharma A/S (NASDAQ:ASND) – Equities researchers at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of Ascendis Pharma A/S in a research note issued to investors on Thursday, September 10th. HC Wainwright analyst M. Kapoor now forecasts that the biotechnology company will post earnings of $3.93 per share for the year, up from their previous forecast of $3.85. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is $3.69 per share. HC Wainwright also issued estimates for Ascendis Pharma A/S’s Q2 2027 earnings at $2.35 EPS, Q3 2027 earnings at $3.05 EPS, Q4 2027 earnings at $4.25 EPS and FY2027 earnings at $11.30 EPS.

Other analysts have also recently issued research reports about the stock. UBS Group set a $345.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, August 31st. Jefferies Financial Group reduced their price target on shares of Ascendis Pharma A/S from $333.00 to $330.00 and set a “buy” rating on the stock in a research report on Monday, August 31st. Weiss Ratings upgraded Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Royal Bank Of Canada upped their price objective on Ascendis Pharma A/S from $280.00 to $290.00 and gave the company an “outperform” rating in a report on Friday, August 14th. Finally, Oppenheimer increased their price objective on Ascendis Pharma A/S from $304.00 to $312.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 1st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Ascendis Pharma A/S has an average rating of “Buy” and an average price target of $310.80.

Ascendis Pharma A/S Price Performance

Shares of ASND stock opened at $239.77 on Monday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.99 and a quick ratio of 2.32. The company has a market capitalization of $14.96 billion, a PE ratio of 18.60 and a beta of 0.35. The firm’s 50-day moving average is $256.82 and its two-hundred day moving average is $242.46. Ascendis Pharma A/S has a 12 month low of $186.05 and a 12 month high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The firm had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million.

Insider Buying and Selling

In related news, Director Jean-Jacques Bienaimé acquired 2,000 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was purchased at an average price of $246.33 per share, with a total value of $492,660.00. Following the transaction, the director owned 2,900 shares of the company’s stock, valued at approximately $714,357. This trade represents a 222.22% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Mads Bodenhoff sold 3,000 shares of Ascendis Pharma A/S stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total transaction of $810,570.00. Following the completion of the sale, the senior vice president owned 3,000 shares of the company’s stock, valued at $810,570. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 40.00% of the company’s stock.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently modified their holdings of the company. Integrated Wealth Concepts LLC acquired a new stake in shares of Ascendis Pharma A/S in the second quarter valued at $380,000. IFP Advisors Inc grew its stake in Ascendis Pharma A/S by 3,491.7% during the 2nd quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 419 shares in the last quarter. Squarepoint Ops LLC grew its stake in Ascendis Pharma A/S by 1,714.3% during the 2nd quarter. Squarepoint Ops LLC now owns 9,686 shares of the biotechnology company’s stock worth $2,583,000 after purchasing an additional 10,286 shares in the last quarter. Baird Financial Group Inc. acquired a new position in Ascendis Pharma A/S during the 2nd quarter worth $2,863,000. Finally, Allworth Financial LP increased its holdings in Ascendis Pharma A/S by 103.4% during the 2nd quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 122 shares during the period.

Key Stories Impacting Ascendis Pharma A/S

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Ascendis authorized a share repurchase program of up to $400 million, which may support earnings per share and signal management’s confidence in the company’s financial position. However, repurchases are discretionary and may be modified or suspended. Ascendis Announces Planned $400 Million Share Repurchase Program
• Positive Sentiment: The company regained exclusive rights to TransCon-based products in metabolic and cardiovascular diseases, including once-monthly TransCon semaglutide for obesity and type 2 diabetes. This gives Ascendis greater control and potential long-term upside if the programs succeed. Ascendis to Regain Rights to TransCon Technology
• Neutral Sentiment: At the Morgan Stanley Global Healthcare Conference, management discussed Ascendis’ strategy and pipeline, but the available transcript information did not identify a major new near-term catalyst. Morgan Stanley Healthcare Conference Transcript
• Negative Sentiment: Investors viewed the Novo Nordisk collaboration termination negatively because Ascendis loses a large partner’s support and must fund and execute development and commercialization itself. Neither company will have continuing financial obligations to the other, increasing uncertainty around the program’s value and timeline.
• Negative Sentiment: Raymond James downgraded ASND to Outperform, adding to pressure from concerns about the partnership change despite the buyback announcement. Raymond James Downgrade

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.